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Vitamin D, upon its discovery one century ago, was classified as a vitamin. This classification still greatly affects our
perception about its biological role. 1,25(OH)2D (now known as the D hormone) is a pleiotropic steroid hormone
that has multiple biologic effects. It is integral to the regulation of calcium homeostasis and bone turnover as well
as having anti-proliferative, pro-differentiation, anti-bacterial, immunomodulatory and anti-inflammatory properties
within the body in various cells and tissues. Vitamin D (cholecalciferol) should be considered a nutritional substrate
that must be ingested or synthesized in sufficient amounts for the further synthesis of the very important regulatory
steroid hormone (D hormone), especially in patients with pediatric rheumatic diseases (PRD).
Vitamin D insufficiency or deficiency was shown to be pandemic and associated with numerous chronic inflammatory
and malignant diseases and even with increased risk of mortality. Several studies have demonstrated that a high
percentage of children with pediatric rheumatic diseases (PRD-e.g., JIA, jSLE) have a vitamin D deficiency or
insufficiency which might correlate with disease outcome and flares. Glucocorticoids used to treat disease may
have a regulatory effect on vitamin D metabolism which can additionally aggravate bone turnover in PRD. An
effort to define the optimal serum 25(OH)D concentrations for healthy children and adults was launched in 2010
but as of now there are no guidelines about supplementation in PRD.
In this review we have tried to summarize the strong evidence now suggesting that as the knowledge of the
optimal approach to diagnosis and treatment PRD has evolved, there is also an emerging need for vitamin D
supplementation as an adjunct to regular disease treatment. So in accordance with new vitamin D recommendations,
we recommend that a child with rheumatic disease, especially if treated with steroids, needs at least 2-3 time higher
doses of vitamin D than the dose recommended for age (approximately 2000 UI/day). Vitamin D supplementation has
become an appealing and important adjunct treatment option in PRD.
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One century after its discovery and three Nobel prizes
awarded for discoveries in this topic [1], we have clear evi-
dences that the so-called vitamin D is in fact a pleiotropic
steroid hormone similar to other steroid hormones. Un-
fortunately, its primary classification into the vitamins still
deeply influences our professional perception about
1,25(OH)2D biological function and impact on the occur-
rence and outcome of the some rheumatic diseases [4]. It* Correspondence: vojinovic.jelena@gmail.com
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article, unless otherwise stated.is necessary to distinguish cholecaliferol (commonly called
vitamin D), a nutritional precursor compound, from the
1,25(OH)2D-vitamin D hormonal form. This hormonal form
is synthetized after a complex, endocrine-regulated biochem-
ical process. This 1,25(OH)2D D hormone has its own endo-
crine, paracrine and autocrine control [5]. As hormone is
defined as a chemical substance produced in one part of the
body that stimulates functional activity in another part [6], it
is clear that what we call vitamin D does not fulfill the vita-
min definition criteria but rather those for a hormone. We
will discuss the biologic roles of vitamin D in this review as
that of the D hormone.
When prescribing medication for the treatment of
rheumatic diseases, most of pediatric rheumatologists do
not recommend vitamins as mandatory, includingd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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that approach. Beside regulation of calcium homeostasis
and bone turnover, the D hormone has proven antipro-
liferative, pro-differentiation, anti-bacterial, immuno-
modulatory and anti-inflammatory properties within the
body in various cells and tissues [2, 3]. This effects can be
achieved only if the D hormone (1,25(OH)2D) itself, or its
agonist, is bound to vitamin D receptor (VDR). The
discovery that vitamin D receptor agonists possess immuno-
modulatory and anti-tumor properties prompted research to
investigate the possibility that these agonists might be used
as a therapeutic agent for different autoimmune and malig-
nant diseases [7,8].
Review
Randomized controlled trials providing recommendations
for vitamin D supplementation in pediatric patients with
PRD are lacking. Yet several recent studies have supported
the importance of and necessity for vitamin D supplementa-
tion within standard treatment protocols and guidelines of
rheumatic diseases in childhood. A study of Arkema et al.
[9] investigated the association between UV-B light exposure
and the risk of developing rheumatoid arthritis (RA) among
women enrolled in two large prospective cohort studies [the
Nurses’ Health Study (NHS) and the NHSII]. These studies
confirmed a significantly decreased risk of RA with higher
UV-B exposure especially between birth and age 15 years.
Nisar et al. [10] published a systemic literature review and
meta-analysis of current evidence on vitamin D in JIA, sum-
marizing data from 19 papers that were largely supporting
positive benefits. Robinson et al. [11] presented data from
Atherosclerosis Prevention in Pediatric Lupus Erythematosus
(APPLE) trial and found vitamin D deficiency to be common
in pediatric lupus and independently associated with elevated
hsCRP and an increased cardiovascular disease risk. Finally,
Holick reviewed recent recommendations and clinical guide-
lines [12] and suggested that vitamin D supplementation of
up to 2000 IU/d appears to be safe and well tolerated in chil-
dren with chronic diseases.
D-hormone synthesis
Cholecalciferol is pre-hormonal form of D hormone that must
be ingested or generated in the skin where one of the rings of
the precursor molecule (7-dehydrocholesterol) is broken down
by ultraviolet B-light (UV-B, sun light). In part this explains
why, when discovered a century ago, it was classified as vitamin.
Actually, as previously noted, this substance is a member of a
group of steroid molecules (secosteroids) with a common A, B,
C and D ring structure derived from the cyclo-pentano-perhy-
drophenanthrene ring structure, very similar to cholesterol [13].
After the UV-B activity, this compound undergoes a
very complex metabolic process that is controlled by clas-
sic endocrine feed-back mechanisms and becomes a bio-
logically active hormone. It must be first hydroxylatedin the liver, at the carbon 25-position by 25-hydroxylase, to
form 25(OH)D, known as a calcidiol or calcifediol. Several
cytochrome P450 (CYP) isoforms (including the mitochon-
drial CYP27A1 and the microsomal CYP2R1, CYP3A4 and
CYP2J3) accomplish this hydroxylation step. CYP2R1 is
thought to be the high-affinity 25-hydroxylase [14]. The
25(OH)D form is the most plentiful and stable pre-
hormonal metabolite of vitamin D in human serum with a
high affinity to bind serum vitamin D binding protein
(VDBP) and other albumin superfamily proteins in the
blood. As such, the 25(OH)D level in the serum is the best
indicator of vitamin D entering the host, either by cutaneous
synthesis or by ingestion in the diet. Nevertheless, this
25(OH)D form is still not a hormone, rather a pre-hormonal
form of the natural hormone, and does not exert any bio-
logical activity in the body [15].
Calcidiol (25(OH)D) is then transported through the
bloodstream, bound to vitamin D binding protein
(VDBP), to the proximal tubule of the kidney, where it is
hydroxylated at the 1α-position to form the final bio-
logically active form of D hormone named calcitriol
(1α,25(OH)2D), by the enzyme 25-hydroxyvitamin D-
1α-hydroxylase (CYP27B1) [16]. Activity of this enzyme
is increased by parathyroid hormone (PTH) secreted by
the parathyroid gland, which is the pivotal activator of
CYP27B1 in proximal tubule cells and decreases with
aging [17]. Thereafter, the synthesized calcitriol becomes
the real D hormone with full biological activity similar
to other steroid hormones. The D hormone increases
intestinal calcium absorption and mobilizes calcium
from the skeleton while calcium level in blood regulates
PTH secretion and CYP27B1 activity. These activities
are clear examples of endocrine regulation due to D hor-
mone production.
D hormone biological activity
For many years it was believed that regulation of calcium
homeostasis within the body with a positive influence on
bone turnover were the only crucial roles of this hor-
mone. These roles were why it was considered to be a
vitamin critical for bone health. This tenet remains cor-
rect, but it is now understood that all monocyte-
macrophage derived cells, including those present in
many tissues and various epithelia, are able to express
1α-hydroxylase and to synthesize calcitriol locally, if
there is a availability of the 25(OH)D substrate [18].
Synthetized D hormone can act on cells and in the
tissues in an autocrine or paracrine manner, and the
synthesized D-hormone (calcitriol) serves as connection
between extracellular stimuli and genomic response of
the cells [19].
It is recognized that 1α,25(OH)2D has high affinity to
bind vitamin D receptor (VDR) due to the presence of
an OH group at the 1α position. The VDR gene shows
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activity, such as kidneys, bone and gut, but has low to
moderate expression in nearly all other human tissues.
VDR, when bound to hormone, heterodimerizes with
the retinoic acid-X-receptor (RXR) and this complex
binds to the vitamin D responsive element (VDRE) act-
ing as a transcriptional factor to enhance or repress gene
transcription [20].
It has been estimated that at least 200 tissues and as
many as 2000 genes are directly or indirectly controlled
by this transcriptional complex [21]. Only high doses of
D hormone can induce genetic effects including immu-
nomodulatory actions [20] while physiological actions
have to be mediated via the genetic and epigenetic
regulatory actions of the VDR transcriptional complex
[22]. VDR protein has been detected both in the cytosol
(associated with sarcoplasmic reticulum Ca2 + −ATPase)
and in plasma membranes. This ubiquitous presence
of the VDR protein may explain some of the rapid
non-genomic actions of 1α,25(OH)2D such as calcium
up-take that are related to calcium homeostasis and
bone mineralization [23].
The signaling pathways of all steroid hormones (gluco-
corticoid, sex hormones) occur through cellular and
nuclear hormone receptors [25]. All of these hormones
influence bone formation and immune regulation. Steroid
nuclear receptors, when bound to their agonist hormone,
under control of co-regulators, catalyze or mediate chroma-
tin remodeling, epigenetic modification, receptor recycling,
and ultimately gene expression [26]. Gene regulation ap-
pears to be modulated by dual modifications of histone
acetylation and DNA methylation. The 1α,25(OH)2D hor-
mone has been shown to be a potent genetic and epigenetic
regulator. This could be explanation for the possible patho-
genetic role of low vitamin D status in immune-mediated
diseases [24, 25].
Using the same signaling pattern, 1,25(OH)2D, locally
produced in the tissues, exerts its effects on several
immune cells, including macrophages, dendritic cells
(DCs), T and B cells.
Macrophages and DCs constitutively express vitamin
D receptor (VDR), whereas VDR expression in T cells is
up-regulated after activation [27]. In macrophages and
monocytes, 1,25(OH)2D positively influences its own
effects by increasing the expression of VDR and the
cytochrome P450 protein CYP27B1 (autocrine regula-
tion). Toll-like-receptor (TLR)-mediated signals can also
increase the expression of VDR.
The 1,25(OH)2D hormone also induces monocyte pro-
liferation and production of interleukin-1 (IL-1) and
cathelicidin (an antimicrobial peptide) by macrophages,
thereby contributing to innate immune response [28, 29].
The 1,25(OH)2D hormone decreases DC maturation,
inhibiting up- regulation of the expression of MHC classII, CD40, CD80 and CD86. In addition, it decreases IL-12
production of DCs and induce production of IL-10.
In T cells, 1,25(OH)2D decreases the production of IL-
2, IL-17 and interferon-γ(IFNγ) and attenuates the cyto-
toxic activity and proliferation of CD4+ and CD8+ T cells
[30]. The 1,25(OH)2D hormone might also promote the
development of forkhead box protein 3 (FOXP3) + regula-
tory T (TReg) cells and IL-10-producing T regulatory type
1 (TR1) cells [31,32]. Finally, 1,25(OH)2D blocks B cell
proliferation, plasma-cell differentiation and immuno-
globulin production [33].
It is clear that the D hormone exerts its effects on
many crucially important immunoregulatory proteins
and cells [34]. Some of them are recognized as possible
causative immune factors for the development of PRDs.
Due to the D hormone’s proven capability to induce
tolerogenic immune response, improve impaired T and
B cell function, and enhance innate immunity response,
a deficiency or insufficiency of D hormone may well
have causative or risk factor effects [35] in pediatric
rheumatic diseases.
D hormone and pediatric rheumatic diseases
Numerous studies suggest that the 1,25(OH)2D hormone
appears to play important roles in the pathogenesis of
several autoimmune diseases, such as diabetes type I, mul-
tiple sclerosis and rheumatoid arthritis. Vitamin D defi-
ciency has been found as a potential risk factor for
increased cardiovascular risk, abnormal HDL and LDL
cholesterol levels, hypertension, hyperglycemia, diabetes
[36–41]. As this hormone affects bone and the immune
system in many profound ways, pediatric rheumatologists
cannot ignore its potential roles in PRDs.
a) Bone health in children
Children and adolescents need to achieve peak bone
mass by age 18 years or enter adulthood with subopti-
mal bone mass and risk of osteoporosis as adults [42].
The inflammatory nature of PRDs may reduce the ability
to achieve peak bone mass [43] due to the inflammation,
pain, decreased activity, and other factors. The necessity
to use glucocorticoids for the treatment of pediatric
rheumatic diseases is an additional risk factor for bone
mass loss during childhood and adolescence [44]. It has
been shown that patients with JIA and jSLE and other
chronic inflammatory diseases have an increased fracture
risk [45]. Glucocorticoids may have a regulatory effect
on vitamin D metabolism which, in the presence of low
vitamin D levels, may additionally negatively affect bone
turnover [46].
The US Centers for Disease Control and Prevention
(CDC) reported in 2006 that healthy children in the US
are vitamin D deficient in approximately 9–11 % at age
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14–18 years [47]. The possible significance of vitamin
D deficiency in JIA was noted more than 20 years ago
[48, 49]. Recently Pelajo et al. [50] reported that 20 %
of all children attending clinic were vitamin D deficient
while children with autoimmune disorders had a 2–3
fold greater probability of being vitamin D deficient
compared to children with non-autoimmune condi-
tions. Soybilgic et al. [51] assessed practices of North
American pediatric rheumatologists regarding monitor-
ing, prevention, and treatment of low bone mineral
density (BMD) in children on long-term glucocorticoid
treatment and found that 79 % "rarely" or "never"
obtained a baseline BMD measurement prior to initi-
ation of glucocorticoid therapy. Yet despite the lack of
BMD assessment, 93 % "frequently" or "always" prescribed
calcium for patients on long-term corticosteroid therapy,
81 % "frequently" or "always" prescribed vitamin D, and
40 % of the survey responders prescribed combined
calcium/vitamin tablets.
It is very important to note that there are no data
about vitamin D formulation and doses used routinely
by pediatric rheumatologists. This may be partly due to
the fact that there are no clear recommendations con-
cerning this issue for pediatric rheumatic diseases. In
adults, the Endocrine Society has recommended two to
three time higher doses of vitamin D supplementation
for adults treated with glucocorticoids than for the
healthy population [52].
b) Juvenile Idiopathic Arthritis (JIA)
Interest and knowledge about vitamin D in JIA has
increased in last decade and deficiency or insufficiency
has been considered as important environmental deter-
minant of the disease [53]. As mentioned, several studies
have shown that vitamin D deficiency is associated with
rheumatoid arthritis (RA) and type 1 diabetes (T1D) and
that supplementation may be inversely associated with
the disease onset [9, 54, 55]. Unfortunately these types
of studies are missing for JIA and other pediatric rheum-
atic diseases. Recent meta-analysis performed by Nisar
et al. [10] included 19 papers reporting values of
25(OH)D and 1,25(OH)D (14 and 11, respectively) in
JIA, using similar assays, but could not find evidence to
link vitamin D deficiency with JIA due to the lack of
agreed definition of vitamin D deficiency in pediatric
population. The main biases of this meta-analysis were
that it did not use cut-off definitions for insufficiency
and deficiency and the heterogeneity of study designs
included in the meta-analysis. Nevertheless it is an
important and useful overview and provides further evi-
dence of the relatively high prevalence of vitamin D defi-
ciency in JIA, especially in the systemic and polyarticularJIA catagories in which children are often treated with
steroids. Mean levels of 25(OH)D within groups stud-
ied were 24.56 ng/ml (range, 11.5–56.4 ng/ml). These
results are in agreement with a recent study of Pelajo
et al. [56] who have found vitamin D deficiency
(≤19 ng/ml) in 13 % and insufficiency (20–29 ng/ml)
in 42 % of JIA patients, including those who were supple-
mented. The same authors could not find any association
of 25(OH)D levels with disease activity (measured with
JADAS-27), except in a subgroup of new-onset JIA who
had non-significant negative correlation. Additional data
about 25(OH)D levels and the influence on disease activity
have been provided by a recent publication of Stagi S et al.
[57]. These authors have confirmed significantly reduced
25(OH)D levels in JIA patients. In their study patients
with active disease and/or frequent relapses have had sig-
nificantly reduced 25(OH)D levels compared to patients
with no active disease or infrequent flares. Two other
studies [58, 59] have found that the percent true cal-
cium absorption is below normal in children with JIA,
while vitamin D supplementation (2000 IU) did appear
to increase serum 25(OH)D and normalize serum cal-
cium levels even without calcium supplementation.
c) Juvenile Systemic Lupus Erythematosus (jSLE) and
Dermatomyositis (JDM)
High prevalence of vitamin D deficiency was shown in
adult SLE but recent studies [60, 61] demonstrated that,
despite vitamin D supplementation, deficiency is present
in juvenile SLE.
Furthermore, vitamin D deficiency strongly correlated
with SLEDAI, C4 level and BMD (low spine and whole
body) [60]. Stagi et al. [61] has shown that jSLE patients
exhibit lower 25(OH)D levels than controls with the lower
values observed in patients with active vs. inactive disease.
Urinary losses of 25(OH)D and vitamin D binding
protein (DBP) could be a reason for the low vitamin D sta-
tus in pediatric lupus patients [62]. Robinson et al. reported
vitamin D deficiency in jSLE patients, an inverse relation-
ship between 25(OH)D levels and proteinuria, and an asso-
ciation with proliferative glomerulonephritis in patients
with jSLE [63]. The same group published very interesting
data as results of the APPLE study (Atherosclerosis
Prevention in Pediatric Lupus Erythematosus) [64].
Briefly, the study confirmed that vitamin D deficiency is
common in jSLE and independently associated with
elevated hsCRP [11].
Additionally, jSLE patients with serum 25(OH)D ≥
20 ng/mL had less mean-max CIMT (carotid intima med-
ial thickness) progression following 3 years of atorvastatin
treatment that could suggest that vitamin D deficiency
may contribute to heightened inflammation and cardio-
vascular risk [65].
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studies, both including a small number of patients,
observed that 25(OH)D level to be lower among children
with high disease activity compared to low disease activity
JDM patients [48, 63]. One recent study confirmed a
significant association of low 25(OH)D serum levels with
idiopathic inflammatory myopathies, including JDM [66].
It is very interesting to point out that association of
vitamin D deficiency with pediatric rheumatic diseases
may not be the only biologically important D hormone
pathway. Polymorphism of genes regulating D hormone
synthesis may be connected with the presence or sever-
ity of many rheumatic diseases [67]. Polymorphisms in
vitamin D pathway related genes has been found to be
associated with increased likelihood of being vitamin D
deficient [68]. Ellis et al. [69] recently published data
about impressive evidence of gene epistasis among all
genes (GC, VDR, CYP24A1, CYP2R1, and DHCR7)
regulating D hormone synthesis as well as the PTPN2
gene which is a vitamin D responsive gene determining
susceptibility to JIA and type 1 diabetes. Several studies
indicated a possible association of VDR receptor gene
polymorphism with RA and JIA [70, 71]. In our study,
we have found that presence of f variant of FokI VDR
polymorphism was associated with a worse outcome and
a longer need for biologic treatment in JIA patients [70].
Optimal D hormone levels
The best method to determine a person’s vitamin D
status is to measure the circulating level of 25(OH)D.
Serum levels of 1α,25(OH)2D are often normal or even
elevated in both children and adults who are vitamin
D deficient due to its very short half-life and tightTable 1 Recommendations for patents at risk for D deficiency (JIA a
Age IOM recommendations for healthy children IOM
chi
EAR IU (μg)/day RDA IU (μg)/day UL IU (μg)/day Da
Infants
0–6 months 400 (10) 1000 (25) 400
6–12 months 400 (10) 1500 (38) 400
Children
1–3 years 400 (10) 600 (15) 2500 (63) 600
4–8 years 400 (10) 600 (15) 3000 (75) 600
Boys
9–13 years 400 (10) 600 (15) 4000 (100) 600
14–18 years 400 (10) 600 (15) 4000 (100) 600
Girls
9–13 years 400 (10) 600 (15) 4000 (100) 400
14–18 years 400 (10) 600 (15) 4000 (100) 400
Adapted from references 52 and 72; EAR-estimated average requirement; RDA-recophysiological control by PTH which can increase renal
production of calcitriol (by stimulating 1α-hydroxylase
activity). The vitamin D hormonal form is synthetized
and accumulated to a large degree in the tissues but
there it cannot be measured [15].
For a long time there has been no consensus on the
optimal concentrations of serum 25(OH)D. Most authors
have used the cut-off values of 10–15 ng/mL to define
vitamin D deficiency. In 2010 the Institute of Medicine
(IOM) concluded that vitamin D deficiency should be
defined as a 25(OH)D level of <20 ng/mL for children and
adults [72]. Based on a study in postmenopausal women
in whom a rise of 25(OH)D level from ~20 ng/mL
to ~32 ng/mL increased their efficiency of intestinal
calcium absorption by 65 %, the Endocrine Clinical
Practice Guidelines Committee of the Endocrine Society
proposed a new definition of vitamin D insufficiency and
sufficiency [52]. Vitamin D deficiency is now defined as
25(OH)D <20 ng/mL, vitamin D insufficiency as 21–
29 ng/mL, and vitamin D sufficiency as >30 ng/mL for
both children and adults. It is suggested that maintenance
of a 25(OH)D level between 40 and 60 ng/mL is ideal and
up to 100 ng/mL is safe [73]. These recommendations are
summarized in Table 1. In adults it was shown that
supplementation of 1000 IU of cholecalciferol per day
increases 25(OH)D level by 7-10 ng/ml and it is be-
lieved that 100 IU can increase 25(OH)D level by as
much as 2–3 ng/ml when serum 25(OH)D is below
15 ng/ml [74].
As IOM recommendations are designed for healthy
individuals of all ages, their direct application in children
with JIA or other rheumatic diseases could be challen-
ging especially due to long term steroid usage and highnd other rheumatic inflammatory diseases)
recommendations for healthy
ldren at risk of vitamin D deficiency
Proposed recommendation for
children with rheumatic diseases
ily requirement IU/day UL, IU/day IU/day
–1000 2000 1000
–1000 2000 1500–2000
–1000 4000 2000
–1000 4000 2000
–1000 4000 2000
–1000 4000 2000
–2000 4000 2000–3000
–2000 4000 2000–3000
mmended daily allowance; UL-tolerable upper intake level
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other rheumatic diseases argue for higher supplemen-
tation doses in these children [52]. It is of great im-
portance for physicians to understand that measured
25(OH)D level is a reflection of food and/or supple-
ment intake, but at the same time it can be a result of
increased utilization and need for this pre-hormonal
substrate in the local tissues (especially immune cells
and bone) in the state of chronic inflammation (Fig. 1).
That is why, for children with rheumatic diseases, we
recommend pediatric rheumatologists to use at least
doubled daily allowance doses (RDA) of cholecalciferol
as vitamin D supplementation, especially for patients
treated with glucocorticoids (Table 1).
As discussed earlier, supplementation with vitamin D
(cholecalciferol) is unfortunately not common in everyday
pediatric rheumatology practice [51]. Additionally there is
huge variety of formulations (ergocalciferol or cholecalcif-
erol, with or without calcium) used in multiple different
dosing regimens. Cholecalciferol (D3) should be the pre-
ferred form for supplementation as it was shown that it
can yield greater increases in 25(OH)D compared to anFig. 1 Vitamin D level estimationequivalent dose of ergocalferol (D2). Additionally, 25(OH)D
is the required substrate for conversion to1,25(OH)2D at
the cellular level and D2 (ergocalciferol) does not have the
long-term potency as D3 [75]. Supplementation with calci-
triol (1,25(OH)2D – final hormonal form) or other vitamin
D analogues is generally recommended only for children
with chronic kidney disease, patients taking anticonvulsants
or suffering from malabsorption syndromes. The patients
are usually unable to metabolize cholecalciferol to the
hormonal form [76].
Among pediatric rheumatologists, there may be fear
that using higher vitamin D doses could carry a risk of
hypercalcemia and toxicity. We doubt this concern is
justified since infants who received the huge doses of
200,000–600,000 IU of vitamin D2 or vitamin D3 orally
for vitamin D deficiency have had no reports of tox-
icity. Rather neonates treated with 2000 IU of vitamin
D3 during the first year of life appeared to have a re-
duced risk of developing an autoimmune disease, ie
type 1 diabetes, and did not experience toxicity [54].
Also, the risk of hypercalcemia can be lowered if add-
itional calcium intake is avoided since it has been shown
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tion [59].
D hormone as a natural compound is necessary to be
present in high concentrations in cells and tissues to
achieve genetic and epigenetic effects. This is why pharma-
ceutical companies focused on the development of more
than 3000 D hormone analogs (agonists) [8]. There is some
evidence that vitamin D analogs can even overcome steroid
resistance [77] and improve disease outcome [78] but ran-
domized controlled trials and other studies are needed.
Conclusion
Vitamin D deficiency has clearly been recognized as
pandemic and connected with numerous non-infectious
diseases with increased incidence in the modern age
(cardiovascular, malignant, autoimmune, cognitive etc.)
and even increased risk of mortality [74, 79–81]. From
epidemiological studies it is clear that vitamin D defi-
ciency is associated with numerous diseases but it is not
totally clear if it is a cause or a effect. Due to disease and
medication effects, children with rheumatic diseases
have additional needs for vitamin D supplementation. It
is reasonable to assume that a child with a rheumatic
disease, especially if treated with steroids, needs at least
double the daily recommended dose of vitamin D for
age (approximately 2000 UI/day) [82]. This high dose is
needed as immunomodulatory and epigenetic benefits
from 1,25(OH)D (hormonal form of vitamin D) can be
achieved only when high levels are present in the tissues
[24]. Vitamin D supplementation is an appealing adjunct
treatment option in JIA and other inflammatory rheum-
atic diseases due to its pleiotropic effects, which may
both minimize bone fragility and attenuate the immune
hyperactivation. It is clear that it is now of great import-
ance that pediatric rheumatologists use vitamin D
supplementation for children with rheumatic diseases as
well as systematically collect data about vitamin D and
disease severity and outcome that will inform Vitamin D
guidelines in the future.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Both authors have made substantive intellectual contributions to the
manuscript. Both authors read and approved the final manuscript.
Author details
1Clinic of Pediatrics, Clinical Center, Faculty of Medicine, University of Nis, Bul
dr Zorana Djindjica 48, 18000 Nis, Serbia. 2Dipartimento di Neuroscienze,
Area del Farmaco e Salute del Bambino (NEUROFARBA), Viale Pieraccini, 24,
50139 Firenze, Italy.
Received: 22 December 2014 Accepted: 22 May 2015
References
1. All Nobel Prizes in Physiology or Medicine - Nobelprize.org [http://
www.nobelprize.org/nobel_prizes/medicine/laureates/].2. Casimir Funk. The etiology of the deficiency diseases. Beri-beri, polyneuritis
in birds, epidemic dropsy, scurvy, experimental scurvy in animals, infantile
scurvy, ship beri-beri, pellagra. J State Med. 1912; 20:341–68.
3. Cutolo M, Pizzorni C, Sulli A. Vitamin D endocrine system involvement in
autoimmune rheumatic diseases. Autoimmun Rev. 2011;11:84–7.
4. Hammes SR. The further redefining of steroid-mediated signaling. Proc Natl
Acad Sci USA. 2003;100(5):21680–2170.
5. Haussler MR et al. The nuclear vitamin D receptor controls the expression of
genes encoding factors which feed the "Fountain of Youth" to mediate
healthful aging. J Steroid Biochem Mol Biol. 2010;121:88–97.
6. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity new etiological
and therapeutical considerations. Ann Rheum Dis. 2007;66:1137–42.
7. De Luca H. Overview of general physiologic features and functions of
vitamin D. Am J Clin Nutr. 2004;80:1689S–96.
8. Vojinovic J. Vitamin D, receptor agonists' anti-inflammatory properties. Ann
N Y Acad Sci. 2014;1317:47–56.
9. Arkema EV, Hart JE, Bertrand KA, Laden F, Grodstein F, Rosner BA, Karlson
EW, Costenbader KH. Exposure to Ultraviolet-B and risk of developing
rheumatoid arthritis among women in the Nurses’ Health Study. Ann
Rheum Dis. 2013;72:506–11.
10. Nisar MK, Masood F, Cookson P, Sansome A, Östörhave AJK. What do we
know about juvenile idiopathic arthritis and vitamin D? A systematic
literature review and meta-analysis of current evidence. Clin Rheumatol.
2013;32(6):729–34.
11. Robinson AB, Tangpricha V, Yow E, Gurion R, Schanberg LE, McComsey GA,
APPLE Investigators. Vitamin D deficiency is common and associated with
increased C-reactive protein in children and young adults with lupus: an
Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy.
Lupus Sci Med. 2014;1(1):e000011. doi:10.1136/lupus-2014-000011.
12. Holick MF. The D-lightful vitamin D for child health. J Parent Enter Nutr.
2012;36 Suppl 1:9S–19.
13. De Luca HF. Vitamin D: the vitamin and the hormone. Fed Proc. 1974;33:2211–9.
14. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic
evidence that the human CYP2R1 enzyme is a key vitamin D 25-
hydroxylase. Proc Natl Acad Sci USA. 2004;101:7711–5.
15. Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357:266–81.
16. Rosen JC. Vitamin D, insufficiency. NEJM. 2011;364:248–54.
17. Jurutka PW, Bartik L, Whitfield GK, Mathern DR, Barthel TK, Gurevich M,
Hsieh JC, Kaczmarska M, Haussler CA, Haussler MR. Vitamin D receptor: key
roles in bone mineral pathophysiology, molecular mechanism of action,
and novel nutritional ligands. J Bone Miner Res. 2007;22:V2–10.
18. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab.
2010;95(2):471–8.
19. Mora R, Iwata M, von Andrian UH. Vitamin effects on the immune system:
vitamins A and D take center stage. Nat Rev Immunol. 2008;8:685–98.
20. Carlberg C, Campbell JM. Vitamin D receptor signaling mechanisms:
Integrated actions of a well-defined transcription factor. Steroids.
2013;78:127–36.
21. Norman AW. Vitamin D, receptor: New assignments for an already busy
receptor. Endocrinology. 2006;147:5542–8.
22. Carlberg C, Molnár F. Current status of vitamin D signaling and its
therapeutic applications. Curr Top Med Chem. 2012;12:1–20.
23. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW. The vitamin D
receptor is present in caveolae enriched plasma membranes and binds
1α,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol. 2004;18:2660–71.
24. Cutolo M, Paolino S, Sulli A, Smith V, Pizzorni C, Seriolo B. Vitamin D, steroid
hormones, and autoimmunity. Ann N Y Acad Sci. 2014;1317:39–46.
25. Sundar KS, Rahman I. Vitamin D and susceptibility of chronic lung diseases;
role of epigenetics. Frontiers in Pharmacology. 2011;2(50):1–10.
26. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC,
Jurutka PW. Molecular mechanisms of vitamin D action. Calcif Tissue Int.
2013;92(2):77–98.
27. Margolis RN, Christakos S. The nuclear receptor superfamily of steroid hormones
and vitamin D gene regulation. Ann N Y Acad Sci. 2010;1192:208–14.
28. Prue HH, Shelley G, Finlay-Jones JJ. Modulation of the immune system by UV
radiation: more than just the effects of vitamin D? Nature Rev. 2011;11:584–96.
29. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives
on the regulation of innate and adaptive immunity. Nat Clin Pract
Endocrinol Metab. 2008;4:80–90.
30. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J,
Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U,
Vojinovic and Cimaz Pediatric Rheumatology  (2015) 13:18 Page 8 of 9Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin
RL. Toll-like receptor triggering of a vitamin D-mediated human
antimicrobial response. Science. 2006;311:1770–3.
31. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D
endocrine system. Nature Clin Pract Rheumatol. 2008;4:404–12.
32. Colin EM, Asmawidjaja PS, van Hamburg JP, Mus AM, van Driel M, Hazes JM,
van Leeuwen JP, Lubberts E. 1,25-dihydroxyvitamin D3 modulates Th17
polarization and interleukin-22 expression by memory T cells from patients
with early rheumatoid arthritis. Arthritis Rheum. 2010;62:132–42.
33. Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3:
a helpful immuno-modulator. Immunology. 2011;134(2):123–39.
doi:10.1111/j.1365-2567.2011.03482.x.
34. Cutolo M, Plebani M, Shoenfeld Y, Adorini L, Tincani A. Vitamin D endocrine
system and the immune response in rheumatic diseases. Vitam Horm.
2011;86:327–51.
35. Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function.
Nutrients. 2013;5(7):2502–21.
36. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental
factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood).
2004;229:1136–42.
37. Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain
and disability in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:745–7.
38. Mauf S, Penna-Martinez M, Jentzsch T, Ackermann H, Henrich D, Radeke HH,
Brück P. Immunomodulatory effects of 25-hydroxyvitamin D3 on monocytic
cell differentiation and influence of vitamin D3 polymorphisms in type 1
diabetes. J Steroid Biochem Mol Biol. 2015;147:17–23.
39. Reis JP, von Mühlen D, Miller 3rd ER, Michos ED, Appel LJ. Vitamin D status
and cardiometabolic risk factors in the United States adolescent population.
Pediatrics. 2009;124(3):e371–9.
40. Mohr S, Garland C, Gorham E, Garland F. The association between ultraviolet B
irradiance, vitamin D status and incidence rates of type 1 diabetes in 51
regions worldwide. Diabetologia. 2008;51:1391–8.
41. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin
D levels and risk of multiple sclerosis. JAMA. 2006;296:2832–8.
42. Cimaz R, Stagi S. Managing pediatric osteoporosis. Int J Clin Rheumatol.
2013;8(5):1–4.
43. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoidinduced
osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–28.
44. von Scheven E, Corbin KJ, Stagi S, Cimaz R. Glucocorticoid-associated
osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms,
diagnosis, and treatment. Curr Osteoporos Rep. 2014;12(3):289–99.
45. Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, Scuccimarri R,
Miettunen PM, Roth J, Atkinson SA, Couch R, Cummings EA, Dent PB,
Ellsworth J, Hay J, Houghton K, Jurencak R, Larché M, LeBlanc C, Oen K,
Saint-Cyr C, Stein R, Stephure D, Taback S, Lentle B, Matzinger M, Shenouda
N, Moher D, Rauch F, Siminoski K, Ward LM; Canadian Steroid-Associated
Osteoporosis in the Pediatric Population (STOPP) Consortium. Incident
vertebral fractures among children with rheumatic disorders 12 months
after glucocorticoid initiation: a national observational study. Arthritis Care
Res (Hoboken). 2012;64(1):122–31.
46. Heaney RP. The vitamin D requirement in health and disease. J Steroid
Biochem Mol Biol. 2005;97:13–9.
47. Looker AC, Johnson CL, Lachner DA, Pfeiffer CM, Schleicher RL, Sempos CT.
Vitamin D status: United States, 2001–2006. NCHS Data Brief. 2011;59:1–8.
48. Reed A, Haugen M, Pachman LM, Langman CB. Abnormalities in serum
osteocalcin values in children with chronic rheumatic diseases. J Pediatr.
1990;116(4):574–80.
49. Reed A, Haugen M, Pachman LM, Langman CB. 25-Hydroxyvitamin D therapy
in children with active juvenile rheumatoid arthritis: short-term effects on
serum osteocalcin levels and bone mineral density. J Pediatr. 1991;119:657–60.
50. Pelajo CF, Lopez-Benitez JM, Miller LC. 25-hydroxyvitamin D levels and
vitamin D deficiency in children with rheumatologic disorders and controls.
J Rheumatol. 2011;38:2000–4.
51. Soybilgic A, Tesher M, Wagner-Weiner L, Onel KB. A survey of steroid-
related osteoporosis diagnosis, prevention and treatment practices of
pediatric rheumatologists in North America. Pediatr Rheumatol Online J.
2014;12:24.
52. Holick MF, Binkley CN, Bischoff-Ferrari AH, Gordon MC, Hanley AD, Heaney
PR, Murad MH, Weaver CM. Evaluation, treatment, and prevention of
vitamin D deficiency: an endocrine society clinical practice guideline.
J Clin Endocrinol Metab. 2011;96(7):1911–30.53. Ellis JA, Munro JE, Ponsonby AL. Possible environmental determinants of
juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49(3):411–25.
54. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin
D and risk of type 1diabetes: a birth-cohort study. Lancet. 2001;358:1500–3.
55. Merlino LA, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated
with rheumatoid arthritis: results from the Iowa Women’s Health Study.
Arthritis Rheum. 2004;50:72–7.
56. Pelajo CF, Lopez-Benitez JM, Kent DM, Price LL, Miller LC, Dawson-Hughes B.
25-hydroxyvitamin D levels and juvenile idiopathic arthritis: is there an
association with disease activity? Rheumatol Int. 2012;32(12):3923–9.
57. Stagi S, Bertini F, Cavalli L, Matucci-Cerinic M, Brandi ML, Falcini F. Determinants
of vitamin D levels in children, adolescents, and young adults with juvenile
idiopathic arthritis. J Rheumatol. 2014;41(9):1884–92.
58. Hillman LS, Cassidy JT, Chanetsa F, Hewett JE, Higgins BJ, Robertson JD.
Percent true calcium absorption, mineral metabolism, and bone mass in
children with arthritis: effect of supplementation with vitamin D3 and
calcium. Arthritis Rheum. 2008;58(10):3255–63.
59. Carrasco R, Lovell DJ, Giannini EH, Henderson CJ, Huang B, Kramer S, Ranz J,
Heubi J, Glass D. Biochemical markers of bone turnover associated with
calcium supplementation in children with juvenile rheumatoid arthritis:
results of a double-blind, placebo controlled intervention trial. Arthritis
Rheum. 2008;58:3932–40.
60. Casella CB, Seguro LPC, Takayama L, Medeiros D, Bonfa E, Pereira RMR.
Juvenile onset systemic lupus erythematosus: a possible role for vitamin D
in disease status and bone health. Lupus. 2012;21:1335–42.
61. Stagi S, Cavalli L, Bertini F, Signorini C, Matucci Cerinic M, de Martino M,
Brandi ML, Falcini F. Vitamin D levels in children, adolescents, and young
adults with juvenile-onset systemic lupus erythematosus: a cross-sectional
study. Lupus. 2014;23:1059–65.
62. Khamiseh G, Vaziri ND, Oveisi F, Ahmadnia MR, Ahmadnia L. Vitamin D
absorption, plasma concentration and urinary excretion of 25-
hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med.
1991;196:210–3.
63. Robinson AB, Rabinovich CE. Hypovitaminosis D is prevalent despite vitamin
D supplementation in pediatric systemic lupus erythematosus. Abstract in:
72nd Annual Meeting ofthe American College of Rheumatology; 2008; San
Francisco, CA.
64. Robinson AB, Thierry-Palmer M, Gibson KL, Rabinovich CE. Disease
activity, proteinuria, and vitamin D status in children with systemic
lupus erythematosus and juvenile dermatomyositis. J Pediatr.
2012;160(2):297–302.
65. Robinson AB, Tangpricha V, Yow E, Gurion R, Schanberg LE, McComsey GA,
APPLE Investigators. Vitamin D status is a determinant of atorvastatin effect
on carotid intima medial thickening progression rate in children with lupus:
an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
substudy. Lupus Sci Med. 2014;1(1):e000037.
66. Azali P, Barbasso Helmers S, Kockum I, Olsson T, Alfredsson L, Charles PJ,
Piehl Aulin K, Lundberg IE. Low serum levels of vitamin D in idiopathic
inflammatory myopathies. Ann Rheum Dis. 2013;72(4):512–6.
67. Berlanga-Taylor AJ, Knight JC. An integrated approach to defining genetic
and environmental determinants for major clinical outcomes involving
vitamin D. Mol Diagn Ther. 2014;18(3):261–72.
68. Suaini NH, Koplin JJ, Ellis JA, Peters RL, Ponsonby AL, Dharmage SC,
Matheson MC, Wake M, Panjari M, Tan HT, Martin PE, Pezic A, Lowe AJ, Martino
D, Gurrin LC, Vuillermin PJ, Tang ML, Allen KJ, HealthNuts Study Investigators.
Environmental and genetic determinants of vitamin D insufficiency in
12-month-old infants. J Steroid Biochem Mol Biol. 2014;144 (Pt B):445–54.
69. Ellis JA, Scurrah KJ, Li YR, Ponsonby AL, Chavez RA, Pezic A, Dwyer T,
Akikusa JD, Allen RC, Becker ML, Thompson SD, Lie BA, Flatø B, Førre O,
Punaro M, Wise C, Finkel TH, Hakonarson H, Munro JE. Epistasis amongst
PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile
idiopathic arthritis. J Steroid Biochem Mol Biol. 2015;145:113–20.
70. Mosaad YM, Hammad EM, Fawzy Z, Abdal Aal IA, Youssef HM, ElSaid TO,
Monir R, El-Deek BS. Vitamin D receptor gene polymorphism as possible risk
factor in rheumatoid arthritis and rheumatoid related osteoporosis. Hum
Immunol. 2014;75(5):452–61.
71. Vojinovic J, Jeftovic T, Lazaraevic D, Susic G. Long term outcome and fokI
VDR polimorphism in JIA patients on anti-TNF treatment [abstract]. Ann
Rheum Dis. 2013;72(Suppl3):739.
72. Institute of Medicine (IOM). Dietary Reference Intakes for Calcium and
Vitamin D. Committee to Review Dietary Reference Intakes for Calcium and
Vojinovic and Cimaz Pediatric Rheumatology  (2015) 13:18 Page 9 of 9Vitamin D. Washington DC: National Academies Press 2011. Available at
http://iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-
Intakes-for-Calcium-and-Vitamin-D/
Vitamin%20D%20and%20Calcium%202010%20Report%20Brief.pdf.
73. Heaney RP. Human serum 25-hydroxycholecalciferol response to extended
oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204–10.
74. Gordon CM, Williams AL, Feldman HA, May J, Sinclair L, Vasquez A, Cox JE.
Treatment of Hypovitaminosis D in Infants and Toddlers. The Journal of
Clinical Endocrinology and Metabolism 2008, 93(7): 2716–2721.
75. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than
vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89(11):5387–91.
76. Hossein-Nezhad A, Holick MF. Optimize dietary intake of vitamin D: an
epigenetic perspective. Curr Opin Clin Nutr Metab Care. 2012;15(6):567–79.
77. Sundar IK, Rahman I. Vitamin D and susceptibility of chronic lung disease:
role of epigenetics. Front Pharamacol. 2011;2(50):1–10.
78. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D,
Pavlica L, Stefanovic D. Disease modifynig and immunoregulatory effects of
high oral dose 1α(OH)D3 in rheumatoid arthritis patients. Clin Exp
Rheumatol. 1999;17:59–62.
79. Wahl DA, Cooper C, Ebeling PR, Eggersdorfer M, Hilger J, Hoffmann K, Josse
R, Kanis JA, Mithal A, Pierroz DD, Stenmark J, Stöcklin E, Dawson-Hughes B.
A global representation of vitamin D status in healthy populations. Arch
Osteoporos. 2012;7(1–2):155–72.
80. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG,
Bjelakovic M, Gluud C. Vitamin D supplementation for prevention of
mortality in adults. Cochrane Database Syst Rev. 2014;1:CD007470.
81. Hossein-Nezhad A, Spira A, Holick MF. Influence of vitamin D status and
vitamin D3 supplementation on genome wide expression of white blood
cells: a randomized double-blind clinical trial. PLoS One. 2013;8(3), e58725.
doi:10.1371/journal.pone.0058725.
82. von Scheven E, Burnham JM. Vitamin D Supplementation in the Pediatric
Rheumatology Clinic. Curr Rheumatol Rep. 2011;13:110–6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
